← Leaderboards
Dennis Joseph Cotter
Medical Technology And Practice Patterns
$3,163,432
Attributed
$3,163,432
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $604.9K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
AHRQ$2,212,646 · 3
NIH$945,786 · 2
FDA$5,000 · 1
By mechanism
R01$2,506,177 · 3
R21$652,255 · 2
R13$5,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical Technology And Practice Patterns
Same institution · by research overlap
- Yi Zhang$287,659
- Mae Thamer$440,096
Others in their field
Top investigators on “Ensure”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$385,823,280
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
EnsureAccountingAdverse OutcomeAnemiaAffectCardiovascular DiseasesCardiovascular SystemAmericanChronic Kidney FailureChronic Kidney InsufficiencyBaseClassificationClinical Practice GuidelineConsensusCostCost EffectiveCreatinineCaringDialysis ProcedureDisease ProgressionDistrict Of ColumbiaDoseEnd Stage Renal FailureErythropoiesis
Grant awards (11)
IMPACT OF THE ESRD PPS REFORM ON EFFICIENCY OF DIALYSIS PROVIDERS AND THE IMPACT ON QUALITY OF CARE AND PATIENTOUTCOMES$253,549
R01 · FY2017 · HS · contact PI
IMPACT OF THE ESRD PPS REFORM ON EFFICIENCY OF DIALYSIS PROVIDERS AND THE IMPACT ON QUALITY OF CARE AND PATIENTOUTCOMES$253,549
R01 · FY2016 · HS · contact PI
ESA Outcomes among Anemic CKD Patients$326,764
R01 · FY2014 · HS · contact PI
ESA Outcomes among Anemic CKD Patients$466,338
R01 · FY2013 · HS · contact PI
ESA Outcomes among Anemic CKD Patients$489,991
R01 · FY2012 · HS · contact PI
Erythropoiesis-stimulating agent use among chronic kidney disease patients$114,900
R21 · FY2012 · DK · contact PI
Erythropoiesis-stimulating agent use among chronic kidney disease patients$114,900
R21 · FY2011 · DK · contact PI
Individualized Treatment Strategies and Optimal Hematocrit Target for Complex Dia$422,455
R21 · FY2010 · HS · contact PI
Erythropoiesis-Stimulating Agents Technical Advisory Committee Meetings$5,000
R13 · FY2010 · FD · contact PI
Epoetin Therapy and Survival of Hemodialysis Patients$351,306
R01 · FY2006 · DK · contact PI
Epoetin Therapy and Survival of Hemodialysis Patients$364,680
R01 · FY2005 · DK